Source comparison
Best MOTS-c Dosage Insulin Sensitivity 2026: Protocol Comparison
The table below summarizes dosing protocols observed across clinical and research contexts, highlighting insulin sensitivity outcomes, side effect profiles, and practical implementation differences. | Protocol | Dosage & Frequency | HOMA-IR Reduction (8 weeks)
This comparison does not assign a generated winner or score.
- The table below summarizes dosing protocols observed across clinical and research contexts, highlighting insulin sensitivity outcomes, side effect profiles, and practical implementation differences.
- | Protocol | Dosage & Frequency | HOMA-IR Reduction (8 weeks) | Time to Measurable Effect | Injection Site Reactions | Best Use Case | Professional Assessment ||—|—|—|—|—|—|| Low-Dose Maintenance | 5mg subcutaneous 2x weekly | 15–20% vs baseline | 6–8 weeks | <5% occurrence | Metabolically healthy individuals maintaining baseline insulin sensitivity; adjunct to dietary intervention | Sufficient for prevention, inadequate for correction of established insulin resistance || Standard Therapeutic | 10mg subcutaneous 2–3x weekly | 28–35% vs baseline | 4–6 weeks | 8–12% occurrence | Primary protocol for HOMA-IR >2.0; most studied range in clinical literature | Optimal balance of efficacy and tolerability; twice weekly maintains effect, three times weekly accelerates mitochondrial adaptation || High-Dose Accelerated | 15mg subcutaneous 3x weekly | 30–38% vs baseline | 3–4 weeks | 18–25% occurrence | Rapid metabolic correction scenarios (pre-surgical optimization, acute metabolic dysfunction)